China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Trial sites expanded: 0 → 9 locations
    • Primary and study completion dates: Jul 31, 2030 to Aug 29, 2030
    • Start date changed from estimate of Sep 24, 2026 to Oct 1, 2026
    • Eligibility criteria expanded, about 7 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
734 trials monitored
See 61 trials at risk
This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Information will be collected on the epidemiology of GN recurrence after kidney transplantation, as well as the outcomes and treatment of the primary disease following kidney transplantation, to provide evidence for subsequent clinical studies, drug development, and translational research. Approximately 300 patients with a confirmed diagnosis of GN before transplantation will be prospectively enrolled. Clinical data will be collected during screening, kidney transplantation, and a 3-year post-transplant follow-up. The frequency of follow-up visits is every 3 months in the 1st year after transplantation, and every 6 months during the 2nd to 3rd years, with a total of 8 follow-up visits. The study will be conducted at 10 sites across China.
Trial Details
NCT Number NCT07783737
Lead Sponsor AstraZeneca
Conditions
(from sponsor)
Glomerulonephritis Kidney Transplant
Related terms Glomerulonephritis
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov